- Home
- ACAD
as 05-09-2025 3:30pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.5B | IPO Year: | 2004 |
| Target Price: | $24.21 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.40 - $20.68 | Next Earning Date: | 05-07-2025 |
| Revenue: | $996,283,000 | Revenue Growth: | 22.42% |
| Revenue Growth (this year): | 13.07% | Revenue Growth (next year): | 10.06% |
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | May 1 '25 | Sell | $14.60 | 1,327 | $19,374.20 | 23,526 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Apr 5 '25 | Sell | $14.82 | 1,028 | $15,234.96 | 23,526 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Apr 5 '25 | Sell | $14.82 | 2,708 | $40,132.56 | 59,456 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Mar 24 '25 | Sell | $17.05 | 1,095 | $18,669.75 | 23,526 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Mar 24 '25 | Sell | $17.05 | 3,171 | $54,065.55 | 59,456 | |
| GAROFALO ELIZABETH A. | ACAD | Director | Mar 5 '25 | Sell | $18.23 | 4,919 | $89,673.37 | 17,595 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Feb 23 '25 | Sell | $19.96 | 475 | $9,481.00 | 23,526 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Feb 23 '25 | Sell | $19.96 | 773 | $15,429.08 | 59,456 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
Thomson Reuters StreetEvents
a day ago
Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call
MT Newswires
a day ago
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $20 From $22, Maintains Hold Rating
GuruFocus.com
2 days ago
ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Associated Press Finance
2 days ago
Acadia: Q1 Earnings Snapshot
Business Wire
2 days ago
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
Argus Research
3 days ago
ACAD: What does Argus have to say about ACAD?
Simply Wall St.
3 days ago
US High Growth Tech Stocks To Watch In Your Portfolio
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.